Mi2000 Totally Implantable Cochlear Implant
DeviceDuring the surgery visit, the Mi2000 Cochlear Implant will be implanted according to the general surgical guidelines and the Mi2000 specific surgical guidelines under general anaesthesia.
NCT Number: NCT04571333
This clinical investigation aims to collect data on the use of the Mi2000 system, a totally implantable cochlear implant system, for the first time in human subjects.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Centre Hospitalier Universitaire de Liège, Department ORL, Liège, Belgium
Cochlear implants (CI) provide a large majority of recipients with a significant degree of speech understanding. However, CI systems rely on external parts, namely Behind-the-Ear (BTE) audio processors with coils or single-unit processors to function. This can have several disadvantages: for instance, the hardware is exposed to external trauma and to the effects of head movement and gravity. The device is also put at risk by humid, dusty, or dirty conditions as well as by physical activities that lead to water exposure such as swimming or sports in general (e.g. perspiration).
In addition, some patients are concerned with the cosmetic appearance of the external parts which are visible (more so than modern behind-the-ear hearing aids), something that may not be desirable to many potential candidates.
This clinical investigation aims to collect data on the use of the Mi2000 system, a totally implantable cochlear implant system, for the first time in human subjects.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
During the surgery visit, the Mi2000 Cochlear Implant will be implanted according to the general surgical guidelines and the Mi2000 specific surgical guidelines under general anaesthesia.
Time frame: up to 16 weeks
Safety of the study device in the intended population will be assessed by an analysis of adverse events (AEs) reported
Time frame: up to 52 weeks
Safety of the study device in the intended population will be assessed by an analysis of adverse events (AEs) reported
Time frame: up to 52 weeks
Speech perception in quiet will be assessed with a monosyllables test
Time frame: up to 52 weeks
Speech perception in noise will be assessed with a sentence test in noise
Time frame: up to 52 weeks
Audiograms will be recorded in unaided and in best aided condition
Time frame: up to 52 weeks
Impedance Field Telemetry (PIFT)
Time frame: up to 52 weeks
Auditory Nerve Response Telemetry (ART)
Time frame: up to 52 weeks
Readout of device parameters stored in the devices internal memory (e.g. log files, battery status, charging status, usage times)
Time frame: up to 52 weeks
Device use will be assessed using a questionnaire, recording user feedback
Time frame: up to 52 weeks
Quality of life will be assessed by the HUI2/3 questionnaire
Time frame: up to 52 weeks
Quality of life will be assessed by hte SSQ12 questionnaire
Time frame: up to 52 weeks
Quality of life will be assessed by the NCIQ questionnaire
Time frame: up to 52 weeks
Subjective rating of sound quality
MED-EL Elektromedizinische Geräte GesmbH
Industry
Feasibility Study: A Totally Implantable Cochlear Implant (Mi2000) for Electrical Stimulation of the Auditory Pathway of Adults With Severe to Profound Sensorineural Hearing Loss
Acronym: TICI
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05621798
Ear Diseases, Hearing Disorders
Kuopio, Finland
View Trial DetailsNCT07028619
Asymmetric Hearing Loss, Cochlear Implant Recipients
Meridian, Idaho, United States
View Trial DetailsNCT05754918
Ear Diseases, Hearing Disorders
Rennes, France
View Trial DetailsNCT05230498
Ear Diseases, Hearing Disorders
Bordeaux, France
View Trial Details